Package Leaflet: Information for the User
OlanzapineSUN 10mg orodispersible tabletsEFG
olanzapine
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the package leaflet:
Olanzapine orodispersible tablets contain the active substance olanzapine. Olanzapine orodispersible tablets belong to a group of medications called antipsychotics and are indicated for the treatment of the following diseases:
a disease with symptoms such as hearing, seeing, or feeling unreal things, mistaken beliefs, unusual suspicion, and a tendency to withdraw. People suffering from this disease may also feel depressed, anxious, or tense.
Olanzapine orodispersible tablets have been shown to prevent the recurrence of these symptoms in patients with bipolar disorder whose manic episodes have responded to treatment with olanzapine.
Consult your doctor or pharmacist before starting to take Olanzapine SUN orodispersible tablets
If you suffer from any of the following diseases, inform your doctor as soon as possible:
If you suffer from dementia, you or your caregiver or family member should inform your doctor if you have ever had a stroke or transient cerebral ischemia.
As a routine precaution, if you are over 65 years old, it is advisable for your doctor to check your blood pressure.
Children and adolescents
Patients under 18 years old should not take Olanzapine orodispersible tablets.
Use of OlanzapineSUNorodispersible tablets with other medications
Only use other medications at the same time as Olanzapine orodispersible tablets if your doctor authorizes it. You may feel drowsy if you combine Olanzapine SUN orodispersible tablets with antidepressants or medications for anxiety or sleep aids (tranquilizers).
Inform your doctor if you are using, have recently used, or may need to use any other medication.
In particular, tell your doctor if you are taking:
Taking Olanzapine SUN orodispersible tablets with alcohol
You should not drink alcohol if you have been administered Olanzapine orodispersible tablets, as the combination with alcohol may cause drowsiness.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication. You should not take this medication during pregnancy unless your doctor recommends it.
You should not take this medication while breastfeeding, as small amounts of olanzapine may pass into breast milk.
The following symptoms may occur in newborns of mothers who have used Olanzapine SUN orodispersible tablets in the last trimester (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, respiratory problems, and difficulty feeding. If your baby has any of these symptoms, contact your doctor.
Driving and using machines
There is a risk of drowsiness when you are taking Olanzapine orodispersible tablets. If this happens to you, do not drive vehicles or use machinery. Consult your doctor.
OlanzapineSUNorodispersible tablets contain aspartame
Patients who cannot take phenylalanine should note that Olanzapine orodispersible tablets contain aspartame, which is a source of phenylalanine. It may be harmful to people with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it properly.
Patients who cannot take mannitol should note that Olanzapine SUN orodispersible tablets contain mannitol. It may produce a mild laxative effect because it contains mannitol.
Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.
Your doctor will tell you how many Olanzapine orodispersible tablets to take and for how long. The daily dose of Olanzapine orodispersible tablets ranges from 5 to 20 mg. Consult your doctor if you experience symptoms again, but do not stop taking Olanzapine orodispersible tablets unless your doctor tells you to.
You should take your Olanzapine orodispersible tablets once a day, following your doctor's instructions. Try to take the tablets at the same time every day. You can take them with or without food. Olanzapine orodispersible tablets are for oral administration.
Olanzapine orodispersible tablets should be placed in the mouth, where they dissolve rapidly with saliva, so they can be swallowed easily. Removing the orodispersible tablet from the mouth intact is difficult. Because the orodispersible tablet is fragile, it should be taken immediately after opening the blister pack. Alternatively, you can also dissolve the tablet in a glass of water or other suitable beverage (orange juice, apple juice, milk, or coffee) immediately before administration.
With some beverages, the mixture may change color and possibly become cloudy. It should be drunk immediately. The orodispersible tablets break easily, so you should handle them with care. Do not touch the tablets with wet hands, as they may break.
If you take more Olanzapine SUN orodispersible tablets than you should
Patients who have taken more Olanzapine orodispersible tablets than they should have experienced the following symptoms: rapid heartbeat, agitation/aggression, speech problems, unusual movements (especially of the face and tongue), and a reduced level of consciousness. Other symptoms may include: acute confusion, seizures (epilepsy), coma, a combination of fever, rapid breathing, sweating, muscle stiffness, and a state of confusion or drowsiness, slowing of respiratory rate, aspiration, increased or decreased blood pressure, and abnormal heart rhythms. Contact your doctor or go to the hospital immediately if you notice any of the above symptoms. It is recommended to show the medication packaging to your doctor.
Consult your doctor, pharmacist, or call the Toxicology Information Service at 91 562 04 20, indicating the medication and the amount used.
If you forget to take Olanzapine SUN orodispersible tablets
Take your tablet as soon as you remember. Do not take two doses in one day.
If you stop taking Olanzapine SUN orodispersible tablets
Do not stop treatment when you feel better. It is very important that you continue taking Olanzapine orodispersible tablets while your doctor tells you to.
If you suddenly stop taking Olanzapine orodispersible tablets, you may experience symptoms such as sweating, insomnia, tremors, anxiety, nausea, or vomiting. Your doctor may suggest gradually reducing the dose before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist
Like all medications, this medication can cause side effects, although not everyone experiences them.
Contact your doctor immediately if you experience:
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Rare side effects (may affect up to 1 in 100 people) include:
Very rare side effects (may affect up to 1 in 1000 people):
During treatment with olanzapine, elderly patients with dementia may experience stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, increased body temperature, skin redness, and walking problems. Deaths have been reported in this particular group of patients.
Olanzapine orodispersible tablets may worsen symptoms in patients with Parkinson's disease.
Severe allergic reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported. DRESS initially manifests with symptoms similar to those of the flu, with a skin rash on the face that spreads to other areas, fever, swelling of the lymph nodes, elevated liver enzyme levels in blood tests, and an increase in a type of white blood cell (eosinophilia).
Reporting side effects:
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the packaging and blister pack. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and unused medications at the SIGRE collection point in your pharmacy. If you have any questions, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Olanzapine SUN orodispersible tablets
Appearance of Olanzapine SUN orodispersible tablets and package contents
Olanzapine SUN 10 mg orodispersible tablets EFG are presented in the form of orodispersible tablets, yellowish in color, slightly speckled, round, with the inscription "OV2" in relief on one side and smooth on the other.
This medication is available in packages of 7, 10, 14, 28, 30, 35, 56, and 70 tablets.
Not all package sizes may be marketed.
Marketing Authorization Holder:
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132 JH Hoofddorp
Netherlands
Manufacturer:
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132 JH Hoofddorp
Netherlands
or
Terapia SA,
Str. Fabricii Nr. 124,
Cluj Napoca, Romania
Further information about this medicinal product can be obtained from the local representative of the Marketing Authorization Holder:
Sun Pharma Laboratories, S.L.
Rambla de Catalunya 53-55
08007 Barcelona, Spain
Tel.:+34 93 342 78 90
This medicinal product is authorized in the EEA member states with the following names:
Austria - Olanzapine Ranbaxy 10mg Schmelzabletten
France - Olanzapine SUN, 10mg Comprime Orodispersible
Germany - Olanzapine Basics 10mg Schmelztabletten
Netherlands - Olanzapine SUN 10mg orodispersible tablet
Poland - Olanzapine Lekam 10mg tabletka Ulegajaca rozpadowi w Jamie ustnej
Romania - Olanzapina Terapia 10mg comprimate orodispersabile
Spain - Olanzapina SUN 10mg comprimidos bucodispersables EFG
Sweden - Olanzapine Ranbaxy 10mg Munsönderfallande tablett
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of OLANZAPINE SUN 10 mg ORALLY DISINTEGRATING TABLETS in October, 2025 is around 105.78 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.